CTOs on the Move

BioMotiv

www.biomotiv.com

 
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biomotiv.com
  • 20600, Chagrin Boulevard
    Shaker Heights, OH USA 44122
  • Phone: 216.455.3216

Executives

Name Title Contact Details

Similar Companies

Sciex

Sciex helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company`s global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis.

Scribe Therapeutics

Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.

Concert Medical

Concert Medical is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gamma Bio

Enabling the Promise of Advanced Therapies

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.